Compare Becton Dickinson and Co (BDX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nomura Holdings Inc — how do they compare? Becton Dickinson and Co trades at $180.3 (market cap $49.41B), while Nomura Holdings Inc trades at $9.95 (market cap $28.46B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Nomura Holdings Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| BDX | NMR | |
|---|---|---|
Market Cap | $49.41B | $28.46B |
Sector | Health | Financials |
52-Week High | $185.39 | $10.04 |
52-Week Low | $138.62 | $6.73 |
Enterprise Value | $65.51B | — |
Dividend Yield | 2.32% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Nomura Holdings (NMR) trades at $9.82, down 1.31% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a robust net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst sentiment is mixed, with a 'Hold' consensus but positive momentum coverage in financial media.
The outlook for NMR is supported by fundamental strength in profitability and revenue expansion, though cash flow volatility and rising debt-to-asset ratios pose risks. The stock presents a value opportunity with a P/E of 11.59, but investors should weigh consistent earnings performance against macroeconomic and sector-specific headwinds affecting financial stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
